+

PE20181451A1 - Anticuerpos neutralizadores del virus de inmunodeficiencia humana - Google Patents

Anticuerpos neutralizadores del virus de inmunodeficiencia humana

Info

Publication number
PE20181451A1
PE20181451A1 PE2018001115A PE2018001115A PE20181451A1 PE 20181451 A1 PE20181451 A1 PE 20181451A1 PE 2018001115 A PE2018001115 A PE 2018001115A PE 2018001115 A PE2018001115 A PE 2018001115A PE 20181451 A1 PE20181451 A1 PE 20181451A1
Authority
PE
Peru
Prior art keywords
antigen
antibody
heavy chain
monoclonal antibody
binding
Prior art date
Application number
PE2018001115A
Other languages
English (en)
Inventor
Mini Balakrishnan
Brian A Carr
John Corbin
Craig S Pace
Nathan D Thomsen
Xue Zhang
Original Assignee
Gilead Sciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gilead Sciences Inc filed Critical Gilead Sciences Inc
Publication of PE20181451A1 publication Critical patent/PE20181451A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1036—Retroviridae, e.g. leukemia viruses
    • C07K16/1045—Lentiviridae, e.g. HIV, FIV, SIV
    • C07K16/1063—Lentiviridae, e.g. HIV, FIV, SIV env, e.g. gp41, gp110/120, gp160, V3, PND, CD4 binding site
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/42—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum viral
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/72—Increased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • AIDS & HIV (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Inorganic Chemistry (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Referido a un anticuerpo monoclonal aislado, o fragmentado de union a antigeno del mismo, que comprende las regiones determinantes de complementariedad de cadena pesada 1-3 (CDR 1-3) establecidas en la SEQ ID NO: 362, 364 y 367 y las CDR de cadena liviana 1-3 establecidas en SEQ ID NO: 395, 396, y 397, donde el anticuerpo o fragmento de union a antigeno del mismo comprende entre cero y cuatro sustituciones de aminoacidos dentro de las CDR, y en donde el anticuerpo o fragmento de union a antigeno del mismo comprende: (a) una cadena pesada del alotipo de IgG1m17; (b) una cadena ligera Lambda2; (c) una region constante de cadena pesada que comprende sustituciones de aminoacidos, como: Ala en posicion 236, Aspen posicion 239, Leu en posicion 330, entre otros; (d) una region variable de cadena pesada que comprende uno o mas de: Ser-Ser-Val o Thr-Gly-Val en las posiciones 82a-82, Gln en la posicion 39, Asn en la posicion 60, entre otros; los cuales son anticuerpos anti-virus de inmunodeficiencia humana (anti-VIH). Tambien se refiere a un polinucleotido aislado que codifica el anticuerpo monoclonal o fragmento de union a antigeno, un vector, una celula y un vector; ademas se refiere a una composicion farmaceutica que comprende el anticuerpo monoclonal, y un metodo para producir el anticuerpo.
PE2018001115A 2015-12-15 2016-12-14 Anticuerpos neutralizadores del virus de inmunodeficiencia humana PE20181451A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201562267652P 2015-12-15 2015-12-15

Publications (1)

Publication Number Publication Date
PE20181451A1 true PE20181451A1 (es) 2018-09-12

Family

ID=58737847

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2018001115A PE20181451A1 (es) 2015-12-15 2016-12-14 Anticuerpos neutralizadores del virus de inmunodeficiencia humana

Country Status (37)

Country Link
US (3) US10239935B2 (es)
EP (2) EP3992206A1 (es)
JP (4) JP6732915B2 (es)
KR (1) KR102165120B1 (es)
CN (2) CN109311967B (es)
AR (1) AR106991A1 (es)
AU (3) AU2016370591C1 (es)
BR (1) BR112018012164A2 (es)
CA (1) CA3008442C (es)
CL (1) CL2018001587A1 (es)
CO (1) CO2018006050A2 (es)
CR (1) CR20180321A (es)
CU (1) CU20180062A7 (es)
CY (1) CY1124756T1 (es)
DK (1) DK3390441T3 (es)
DO (2) DOP2018000146A (es)
EA (2) EA201891186A1 (es)
EC (1) ECSP18045028A (es)
ES (1) ES2897756T3 (es)
HU (1) HUE056243T2 (es)
IL (1) IL259832B (es)
LT (1) LT3390441T (es)
MA (1) MA44077A (es)
MX (2) MX2018007288A (es)
MY (2) MY196200A (es)
NZ (1) NZ743713A (es)
PE (1) PE20181451A1 (es)
PH (1) PH12018501281A1 (es)
PL (1) PL3390441T3 (es)
SA (1) SA518391778B1 (es)
SG (2) SG10202108793TA (es)
SI (1) SI3390441T1 (es)
SV (1) SV2018005710A (es)
TW (2) TWI735491B (es)
UA (1) UA125819C2 (es)
WO (1) WO2017106346A2 (es)
ZA (1) ZA201803783B (es)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140294812A1 (en) * 2013-03-15 2014-10-02 Xencor, Inc. Fc variants that improve fcrn binding and/or increase antibody half-life
EP3052132B1 (en) 2013-09-30 2020-07-29 Beth Israel Deaconess Medical Center, Inc. Antibody therapies for human immunodeficiency virus (hiv)
CA2972259A1 (en) 2014-12-26 2016-06-30 Emory University N4-hydroxycytidine and derivatives and anti-viral uses related thereto
PL3365366T3 (pl) 2015-10-25 2022-01-31 Sanofi Trójspecyficzne i/lub trójwalentne białka wiążące do zapobiegania lub leczenia zakażenia HIV
EP3992206A1 (en) 2015-12-15 2022-05-04 Gilead Sciences, Inc. Human immunodeficiency virus neutralizing antibodies
DK3443006T5 (da) 2016-04-13 2024-09-16 Sanofi Sa Trispecifikke og/eller trivalente bindingsproteiner
AU2017248671B2 (en) 2016-04-13 2024-06-20 Sanofi Trispecific and/or trivalent binding proteins
TWI794171B (zh) 2016-05-11 2023-03-01 美商滬亞生物國際有限公司 Ｈｄａｃ抑制劑與ｐｄ-ｌ１抑制劑之組合治療
TWI808055B (zh) 2016-05-11 2023-07-11 美商滬亞生物國際有限公司 Hdac 抑制劑與 pd-1 抑制劑之組合治療
AU2018290228B2 (en) * 2017-06-21 2021-07-01 Gilead Sciences, Inc. Multispecific antibodies that target HIV gp120 and CD3
GB2581936B (en) 2017-12-07 2021-02-10 Univ Emory N4-hydroxycytidine and derivatives and anti-viral uses related thereto
BR112020012308A2 (pt) * 2017-12-19 2020-11-24 The Rockefeller University variantes domínios de igg fc humanos com função de efeito melhorada
CA3091437A1 (en) * 2018-02-21 2019-08-29 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Neutralizing antibodies to hiv-1 env and their use
WO2019226829A1 (en) * 2018-05-22 2019-11-28 Beth Israel Deaconess Medical Center, Inc. Antibody therapies for human immunodeficiency virus (hiv)
EP3810755A4 (en) 2018-06-19 2021-12-01 Nantcell, Inc. COMPOSITIONS AND METHODS OF TREATMENT FOR HIV
BR112020025721A2 (pt) 2018-07-03 2021-04-06 Gilead Sciences, Inc. Anticorpos que visam a gp120 do hiv e métodos de uso
US20220048988A1 (en) * 2018-09-13 2022-02-17 Children's National Medical Center Cells expressing antibodies targeting human immunodeficiency virus and methods of using the same
WO2020086782A1 (en) * 2018-10-24 2020-04-30 The Wistar Institute Of Anatomy And Biology Dna antibody constructs for use against hiv
EP4292659A3 (en) * 2018-12-19 2024-03-20 Humabs Biomed SA Antibodies that neutralize hepatitis b virus and uses thereof
AU2020207265A1 (en) * 2019-01-07 2021-08-12 Thomas Jefferson University Multi-functional fusion proteins and uses thereof
UA127822C2 (uk) 2019-03-22 2024-01-10 Гіліад Сайєнсіз, Інк. Місткові трициклічні карбамоїлпіридонові сполуки та їх фармацевтичне застосування
US11613576B2 (en) 2019-04-09 2023-03-28 Sanofi Trispecific binding proteins, methods, and uses thereof
TWI762925B (zh) * 2019-05-21 2022-05-01 美商基利科學股份有限公司 鑑別對使用gp120 v3聚醣導向之抗體的治療敏感之hiv病患的方法
AU2020311902A1 (en) * 2019-07-08 2022-01-27 California Institute Of Technology Anti-HIV vaccine antibodies with reduced polyreactivity
AU2020315598B2 (en) 2019-07-16 2024-12-12 Gilead Sciences, Inc. HIV vaccines and methods of making and using
JP7502861B2 (ja) 2019-12-27 2024-06-19 旭化成株式会社 標的物質と両親媒性高分子との複合体の形成反応の反応温度の評価方法
JP2023518433A (ja) 2020-03-20 2023-05-01 ギリアード サイエンシーズ， インコーポレイテッド ４’－ｃ－置換－２－ハロ－２’－デオキシアデノシンヌクレオシドのプロドラッグ並びにその製造法及び使用法
WO2021207635A1 (en) * 2020-04-09 2021-10-14 The George Washington University Prussian blue nanoparticles functionalization with latency reversing agents and broadly neutralizing antibodies, and applications thereof
CA3187085A1 (en) 2020-08-25 2022-03-03 Manuel Baca Multi-specific antigen binding molecules targeting hiv and methods of use
TWI815194B (zh) 2020-10-22 2023-09-11 美商基利科學股份有限公司 介白素2-Fc融合蛋白及使用方法
AU2021377614B2 (en) 2020-11-11 2025-05-15 Gilead Sciences, Inc. METHODS OF IDENTIFYING HIV PATIENTS SENSITIVE TO THERAPY WITH gp120 CD4 BINDING SITE-DIRECTED ANTIBODIES
US20230000973A1 (en) * 2021-06-25 2023-01-05 Janssen Vaccines & Prevention B.V. Combinations of Vaccines and Neutralizing Antibodies for Treating Human Immunodeficiency Virus Infection in Subjects Undergoing Antiretroviral Treatment
US20230212148A1 (en) 2021-12-03 2023-07-06 Gilead Sciences, Inc. Therapeutic compounds for hiv virus infection
MX2024006396A (es) 2021-12-03 2024-06-04 Gilead Sciences Inc Compuestos terapeuticos para la infeccion por el virus de inmunodeficiencia humana (vih).
CN118355020A (zh) 2021-12-03 2024-07-16 吉利德科学公司 Hiv病毒感染的治疗性化合物
TWI856796B (zh) 2022-04-06 2024-09-21 美商基利科學股份有限公司 橋聯三環胺甲醯基吡啶酮化合物及其用途
TWI867601B (zh) 2022-07-01 2024-12-21 美商基利科學股份有限公司 可用於ｈｉｖ病毒感染之疾病預防性或治療性治療的治療性化合物
KR20250036855A (ko) 2022-07-12 2025-03-14 길리애드 사이언시즈, 인코포레이티드 Hiv 면역원성 폴리펩타이드 및 백신, 및 이들의 용도
WO2024044477A1 (en) 2022-08-26 2024-02-29 Gilead Sciences, Inc. Dosing and scheduling regimen for broadly neutralizing antibodies
WO2024076915A1 (en) 2022-10-04 2024-04-11 Gilead Sciences, Inc. 4'-thionucleoside analogues and their pharmaceutical use
TW202444363A (zh) 2023-04-19 2024-11-16 美商基利科學股份有限公司 殼體抑制劑之給藥方案
TW202504592A (zh) 2023-05-31 2025-02-01 美商基利科學股份有限公司 固體形式
TW202448483A (zh) 2023-05-31 2024-12-16 美商基利科學股份有限公司 用於ｈｉｖ之治療性化合物
WO2025029247A1 (en) 2023-07-28 2025-02-06 Gilead Sciences, Inc. Weekly regimen of lenacapavir for the treatment and prevention of hiv
WO2025042394A1 (en) 2023-08-23 2025-02-27 Gilead Sciences, Inc. Dosing regimen of hiv capsid inhibitor
WO2025049708A1 (en) * 2023-08-31 2025-03-06 International Aids Vaccine Initiative Human neutralizing antibodies against hiv env
WO2025080879A1 (en) 2023-10-11 2025-04-17 Gilead Sciences, Inc. Bridged tricyclic carbamoylpyridone compounds and uses thereof
WO2025080863A1 (en) 2023-10-11 2025-04-17 Gilead Sciences, Inc. Bridged tricyclic carbamoylpyridone compounds and uses thereof
WO2025080850A1 (en) 2023-10-11 2025-04-17 Gilead Sciences, Inc. Bridged tricyclic carbamoylpyridone compounds and uses thereof

Family Cites Families (85)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5913521B2 (ja) 1975-06-19 1984-03-30 メイトウサンギヨウ カブシキガイシヤ 磁性酸化鉄・デキストラン複合体の製造法
US4452773A (en) 1982-04-05 1984-06-05 Canadian Patents And Development Limited Magnetic iron-dextran microspheres
US4454106A (en) 1982-06-07 1984-06-12 Gansow Otto A Use of metal chelate conjugated monoclonal antibodies
US4472509A (en) 1982-06-07 1984-09-18 Gansow Otto A Metal chelate conjugated monoclonal antibodies
PT81498B (pt) 1984-11-23 1987-12-30 Schering Ag Processo para a preparacao de composicoes para diagnostico contendo particulas magneticas
US4831175A (en) 1986-09-05 1989-05-16 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Backbone polysubstituted chelates for forming a metal chelate-protein conjugate
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
US7041293B1 (en) 1990-04-03 2006-05-09 Genentech, Inc. HIV env antibodies
US5571894A (en) 1991-02-05 1996-11-05 Ciba-Geigy Corporation Recombinant antibodies specific for a growth factor receptor
EP1400536A1 (en) 1991-06-14 2004-03-24 Genentech Inc. Method for making humanized antibodies
FI941572L (fi) 1991-10-07 1994-05-27 Oncologix Inc Anti-erbB-2-monoklonaalisten vasta-aineiden yhdistelmä ja käyttömenetelmä
ATE207080T1 (de) 1991-11-25 2001-11-15 Enzon Inc Multivalente antigen-bindende proteine
EP1514934B1 (en) 1992-02-06 2008-12-31 Novartis Vaccines and Diagnostics, Inc. Biosynthetic binding protein for cancer marker
US5910486A (en) 1994-09-06 1999-06-08 Uab Research Foundation Methods for modulating protein function in cells using, intracellular antibody homologues
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
US6815201B2 (en) 1997-09-08 2004-11-09 The Public Health Research Institute Of The City Of New York, Inc. HIV-1 gp120 V1/V2 domain epitopes capable of generating neutralizing antibodies
US7317091B2 (en) 2002-03-01 2008-01-08 Xencor, Inc. Optimized Fc variants
US7662925B2 (en) 2002-03-01 2010-02-16 Xencor, Inc. Optimized Fc variants and methods for their generation
US20040132101A1 (en) 2002-09-27 2004-07-08 Xencor Optimized Fc variants and methods for their generation
US8388955B2 (en) 2003-03-03 2013-03-05 Xencor, Inc. Fc variants
US20090010920A1 (en) 2003-03-03 2009-01-08 Xencor, Inc. Fc Variants Having Decreased Affinity for FcyRIIb
US7429565B2 (en) 2003-04-25 2008-09-30 Gilead Sciences, Inc. Antiviral phosphonate analogs
US20070148170A1 (en) 2005-10-03 2007-06-28 Desjarlais John R Fc Variants With Optimized Fc Receptor Binding Properties
LT2857418T (lt) 2004-02-06 2017-09-25 University Of Massachusetts Antikūnai prieš clostridium difficile toksinus ir jų panaudojimas
DK1778251T3 (da) 2004-07-27 2011-07-18 Gilead Sciences Inc Nukleosidphosphatkonjugater som anti-HIV-midler
WO2006050219A2 (en) 2004-10-29 2006-05-11 Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Broadly cross-reactive hiv-1 neutralizing human monoclonal antibodies
US8546543B2 (en) 2004-11-12 2013-10-01 Xencor, Inc. Fc variants that extend antibody half-life
US8367805B2 (en) 2004-11-12 2013-02-05 Xencor, Inc. Fc variants with altered binding to FcRn
EP2325206B1 (en) 2004-11-12 2014-03-19 Xencor, Inc. Fc variants with altered binding to fcrn
US20100056898A1 (en) 2005-06-13 2010-03-04 Mckenna David R Objective Methods of Estimating Age of Animals and Carcasses
TWI382019B (zh) 2005-08-19 2013-01-11 Array Biopharma Inc 作為類鐸受體（ｔｏｌｌ-ｌｉｋｅ ｒｅｃｅｐｔｏｒ）調節劑之胺基二氮雜呯
TWI404537B (zh) 2005-08-19 2013-08-11 Array Biopharma Inc 作為類鐸受體（ｔｏｌｌ-ｌｉｋｅ ｒｅｃｅｐｔｏｒ）調節劑之８-經取代苯并氮雜呯
EP1803814A1 (en) 2005-12-27 2007-07-04 SIGMA-TAU Industrie Farmaceutiche Riunite S.p.A. Method of improving the antibody selection capacity in phage-display library
WO2008140579A2 (en) 2006-11-17 2008-11-20 New York University Induction of broadly reactive neutralizing antibodies by focusing the immune response on v3 epitopes of the hiv-1 gp120 envelope
JP4783325B2 (ja) 2007-04-09 2011-09-28 株式会社神戸製鋼所 高温排ガスの処理方法
EA024359B1 (ru) 2007-06-29 2016-09-30 Джилид Сайэнс, Инк. Пуриновые производные и их применение в качестве модуляторов толл-подобного рецептора 7
SG185995A1 (en) 2007-11-16 2012-12-28 Gilead Sciences Inc Inhibitors of human immunodeficiency virus replication
CA2732437C (en) 2008-08-01 2017-11-21 Ventirx Pharmaceuticals, Inc. Toll-like receptor agonist formulations and their use
WO2010056898A2 (en) 2008-11-12 2010-05-20 University Of Maryland, Baltimore Rapid expression cloning of human monoclonal antibodies from memory b cells
KR101687841B1 (ko) 2008-12-09 2016-12-19 길리애드 사이언시즈, 인코포레이티드 톨-유사 수용체의 조절제
WO2010096678A2 (en) 2009-02-20 2010-08-26 International Aids Vaccine Initiative Recombinant viral vectors
SI3260136T1 (sl) 2009-03-17 2021-05-31 Theraclone Sciences, Inc. Humani imunodeficientni virus (HIV)-nevtralizirajoča protitelesa
EP2246364A1 (en) 2009-04-29 2010-11-03 Pierre Fabre Médicament Anti CXCR4 antibodies for the treatment of HIV
US8338441B2 (en) 2009-05-15 2012-12-25 Gilead Sciences, Inc. Inhibitors of human immunodeficiency virus replication
RU2016108987A (ru) 2009-08-18 2018-11-26 Вентиркс Фармасьютикалз, Инк. Замещенные бензоазепины в качестве модуляторов toll-подобного рецептора
JP5756804B2 (ja) 2009-08-18 2015-07-29 ベンティアールエックス ファーマシューティカルズ， インコーポレイテッドＶｅｎｔｉＲｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ，Ｉｎｃ． Ｔｏｌｌ様レセプターモジュレーターとしての置換ベンゾアゼピン
EA020488B1 (ru) 2009-10-22 2014-11-28 Джилид Сайэнс, Инк. Производные пурина или деазапурина для применения при лечении вирусных инфекций и других заболеваний
US20130165489A1 (en) 2010-05-03 2013-06-27 The Trustees Of The University Of Pennsylvania Small Molecule Modulators of HIV-1 Capsid Stability and Methods Thereof
PT2588455T (pt) 2010-07-02 2018-06-29 Gilead Sciences Inc Derivados de ácido 2-quinolinil-acético como compostos antivirais para vih
CA2802308C (en) 2010-07-02 2018-08-28 Lianhong Xu Napht-2-ylacetic acid derivatives to treat aids
CN102374226A (zh) 2010-08-06 2012-03-14 深圳富泰宏精密工业有限公司 套筒、铰链结构及应用该铰链结构的便携式电子装置
EP3556396B1 (en) 2010-08-31 2022-04-20 Theraclone Sciences, Inc. Human immunodeficiency virus (hiv)-neutralizing antibodies
WO2012040904A1 (zh) 2010-09-28 2012-04-05 富士通株式会社 激活共存工作模式的方法及基站、用户设备和系统
KR101866893B1 (ko) 2010-10-01 2018-06-14 벤티알엑스 파마슈티칼스 인코포레이티드 Tlr 아고니스트의 치료적 용도 및 병용 요법
JP6092107B2 (ja) 2010-10-01 2017-03-08 ベンティアールエックス ファーマシューティカルズ， インコーポレイテッドＶｅｎｔｉＲｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ，Ｉｎｃ． アレルギー性疾患の治療方法
KR101416437B1 (ko) 2010-11-03 2014-07-10 한국전자통신연구원 파장 가변 외부 공진 레이저 발생 장치
US9562038B2 (en) 2010-11-18 2017-02-07 Yale University Bifunctional molecules with antibody-recruiting and entry inhibitory activity against the human immunodeficiency virus
BR112013017947A2 (pt) 2011-01-12 2018-12-18 Array Biopharma Inc benzoazepinas substituídas como moduladores de receptor toll-like
AU2012205486B2 (en) 2011-01-12 2017-02-02 Array Biopharma, Inc. Substituted benzoazepines as toll-like receptor modulators
WO2012106578A1 (en) * 2011-02-04 2012-08-09 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services HIV NEUTRALIZING ANTIBODIES HAVING MUTATIONS IN CONSTANT DOMAIN (Fc)
KR102058946B1 (ko) 2011-04-08 2019-12-24 얀센 사이언시즈 아일랜드 언리미티드 컴퍼니 바이러스 감염 치료를 위한 피리미딘 유도체
PE20141066A1 (es) 2011-04-21 2014-09-05 Gilead Sciences Inc Compuestos de benzotiazol
LT2709989T (lt) 2011-05-18 2018-04-10 Janssen Sciences Ireland Uc Chinazolino dariniai, skirti virusinių infekcijų ir kitų ligų gydymui
PT2729448E (pt) 2011-07-06 2015-12-02 Gilead Sciences Inc Compostos para o tratamento de vih
CN102863512B (zh) 2011-07-07 2016-04-20 上海泓博智源医药技术有限公司 抗病毒化合物
EP2794613B1 (en) 2011-12-20 2017-03-29 Boehringer Ingelheim International GmbH Condensed triclyclic compounds as inhibitors of hiv replication
EA026368B1 (ru) 2011-12-21 2017-03-31 Новира Терапьютикс, Инк. Противовирусные агенты против гепатита в
EA033907B1 (ru) 2012-02-08 2019-12-09 Янссен Сайенсиз Айрленд Юси Производные пиперидино-пиримидина, фармацевтическая композиция и их применение
KR20150002573A (ko) 2012-04-20 2015-01-07 길리애드 사이언시즈, 인코포레이티드 벤조티아졸-6-일 아세트산 유도체 및 ｈｉｖ 감염을 치료하기 위한 이의 용도
US11149069B2 (en) 2012-08-03 2021-10-19 Dana-Farber Cancer Institute, Inc. Compositions and methods for conformationally stabilizing primate immunodeficiency virus envelope glycoprotein trimers
MY183534A (en) 2012-08-10 2021-02-25 Janssen Sciences Ireland Uc Alkylpyrimidine derivatives for the treatment of viral infections and further diseases
KR102217111B1 (ko) 2012-10-10 2021-02-18 얀센 사이언시즈 아일랜드 언리미티드 컴퍼니 바이러스 감염 및 다른 질환 치료를 위한 피롤로[3,2-d]피리미딘 유도체
EA035431B1 (ru) 2012-11-16 2020-06-15 Янссен Сайенсиз Айрлэнд Юси Гетероциклические замещенные производные 2-амино-хиназолина в качестве модуляторов tlr7 и/или tlr8 для лечения вирусных инфекций
EP3608325B1 (en) 2012-12-21 2022-07-06 Gilead Sciences, Inc. Polycyclic-carbamoylpyridone compounds and their pharmaceutical use
MX2015008467A (es) 2012-12-27 2015-09-23 Japan Tobacco Inc Derivado sustituido de espiropirido[1,2-a]pirazina y uso medico del mismo como inhibidor de la integrasa del virus de inmunodeficiencia humana.
WO2014124457A1 (en) * 2013-02-11 2014-08-14 University Of Louisville Research Foundation, Inc. Methods for producing antibodies
UA118751C2 (uk) 2013-02-21 2019-03-11 ЯНССЕН САЙЄНСІЗ АЙРЛЕНД ЮСі Похідні 2-амінопіримідину для лікування вірусних інфекцій
WO2014165128A2 (en) 2013-03-12 2014-10-09 Novira Therapeutics, Inc. Hepatitis b antiviral agents
EP3052132B1 (en) 2013-09-30 2020-07-29 Beth Israel Deaconess Medical Center, Inc. Antibody therapies for human immunodeficiency virus (hiv)
JP2017501986A (ja) 2013-12-02 2017-01-19 アーロン ダイアモンド エイズ リサーチ センター ネイティブな構成を有する二重特異性抗体を使用した細胞レセプターアンカリングによる改善されたｈｉｖ−１中和抗体の効力及び幅
CN106714800B (zh) * 2014-07-11 2021-09-03 吉利德科学公司 用于治疗hiv的toll样受体调节剂
LT3097102T (lt) 2015-03-04 2018-01-25 Gilead Sciences, Inc. 4,6-diamino-pirido[3,2-d]pirimidino junginiai, moduliuojantys į toll panašius receptorius
EP3992206A1 (en) 2015-12-15 2022-05-04 Gilead Sciences, Inc. Human immunodeficiency virus neutralizing antibodies

Also Published As

Publication number Publication date
EA202091898A1 (ru) 2021-06-22
ES2897756T3 (es) 2022-03-02
JP2019506142A (ja) 2019-03-07
EP3390441B1 (en) 2021-08-25
US11655285B2 (en) 2023-05-23
UA125819C2 (uk) 2022-06-15
TWI814056B (zh) 2023-09-01
JP6732915B2 (ja) 2020-07-29
BR112018012164A2 (pt) 2018-12-04
ZA201803783B (en) 2019-08-28
CN114848812B (zh) 2025-01-10
CY1124756T1 (el) 2022-07-22
IL259832B (en) 2022-06-01
JP6936361B2 (ja) 2021-09-15
SA518391778B1 (ar) 2021-09-07
CA3008442C (en) 2022-03-08
EP3390441A2 (en) 2018-10-24
PL3390441T3 (pl) 2022-01-10
DOP2021000022A (es) 2021-02-28
KR20180085804A (ko) 2018-07-27
MY196200A (en) 2023-03-22
AU2021261910A1 (en) 2021-12-02
KR102165120B1 (ko) 2020-10-13
AU2019275625B2 (en) 2021-09-09
AU2016370591A1 (en) 2018-07-12
AR106991A1 (es) 2018-03-07
AU2021261910B2 (en) 2024-04-18
WO2017106346A3 (en) 2017-09-21
AU2019275625A1 (en) 2020-01-02
US20190211083A1 (en) 2019-07-11
CU20180062A7 (es) 2018-08-06
TWI735491B (zh) 2021-08-11
CN114848812A (zh) 2022-08-05
US10239935B2 (en) 2019-03-26
DK3390441T3 (da) 2021-10-11
SG11201804787UA (en) 2018-07-30
MX2022013524A (es) 2022-11-16
CO2018006050A2 (es) 2018-06-20
WO2017106346A2 (en) 2017-06-22
JP2022163192A (ja) 2022-10-25
US10882898B2 (en) 2021-01-05
CN109311967A (zh) 2019-02-05
US20210155676A1 (en) 2021-05-27
SV2018005710A (es) 2018-09-19
US20170190763A1 (en) 2017-07-06
CA3008442A1 (en) 2017-06-22
JP7126594B2 (ja) 2022-08-26
TW201731870A (zh) 2017-09-16
AU2016370591C1 (en) 2020-09-03
MY186414A (en) 2021-07-22
MX2018007288A (es) 2018-09-28
JP2022000025A (ja) 2022-01-04
CL2018001587A1 (es) 2018-09-28
MA44077A (fr) 2021-05-05
ECSP18045028A (es) 2018-06-30
EA201891186A1 (ru) 2018-12-28
EP3992206A1 (en) 2022-05-04
PH12018501281A1 (en) 2019-02-04
HUE056243T2 (hu) 2022-02-28
CN109311967B (zh) 2022-03-04
LT3390441T (lt) 2021-11-10
CR20180321A (es) 2018-08-21
JP2020120689A (ja) 2020-08-13
AU2016370591B2 (en) 2019-09-12
DOP2018000146A (es) 2018-06-30
IL259832A (en) 2018-07-31
NZ743713A (en) 2020-01-31
SG10202108793TA (en) 2021-09-29
TW202222826A (zh) 2022-06-16
SI3390441T1 (sl) 2021-11-30

Similar Documents

Publication Publication Date Title
PE20181451A1 (es) Anticuerpos neutralizadores del virus de inmunodeficiencia humana
DOP2021000026A (es) Anticuerpos que se unen específicamente a los epítopos del virus del zika y usos de los mismos
AR106184A1 (es) Proteínas de unión a pd-1 y sus métodos de uso
CL2023002239A1 (es) Anticuerpos de b7-h4 y métodos para usarlos
EA202090812A1 (ru) Новые биспецифические полипептидные комплексы
CL2019001926A1 (es) Anticuerpos anti-tigit y fragmentos de unión a antígeno; composición farmacéutica que los comprende; polinenucleótido que codifica dicho anticuerpo; vector que los comprende, célula hospedera; método para producir dicho anticuerpo o fragmento de unión a antígeno del mismo; y uso en el tratamiento del cáncer. (divisional de solicitud 310-2017).
CL2019002310A1 (es) Receptores quiméricos y métodos de uso de los mismos (divisional solicitud 201802797)
AR111418A1 (es) Dominios de unión a antígeno humanizados y métodos de uso
PE20240218A1 (es) Anticuerpos madurados por afinidad y humanizados para fcrh5
PE20240111A1 (es) Moleculas de union a pd-1 y metodos de uso de las mismas
CO2018005932A2 (es) Moléculas biespecíficas que tienen inmunorreactividad con pd-1 y ctla-4, y métodos de uso de las mismas
EA201600276A1 (ru) Анти-il-17-антитела, способ их получения и способ применения
EA201791961A1 (ru) Антитела, специфичные к cd47 и pd-l1
PE20181270A1 (es) Anticuerpo que neutraliza el virus respiratorio sincitial humano
PE20190737A1 (es) Anticuerpos anti-cd27
PE20141908A1 (es) Anticuerpos cd47 y metodos de uso los mismos
HRP20240719T1 (hr) Kimerna i humanizirana monoklonska protutijela protiv ljudskog ctla4 i njihova upotreba
MX377753B (es) Anticuerpos anti-lag3 y fragmentos de union a antigeno.
EA201590208A1 (ru) Усиление активности т-клеток car путем совместного введения биспецифического антитела
JOP20190002A1 (ar) أجسام مضادة (أنتي – بي دي – 1) وطريقة الإنتاج وطريقة استخدام كل منهم
AR096617A1 (es) Anticuerpos anti-tweakr y sus usos
EA201591091A1 (ru) Антигенсвязывающие белки для bcma
NZ630610A (en) Tau peptides, anti-tau antibodies, and methods of use thereof
MX366359B (es) Anticuerpos humanizados contra la molecula de adhesion celular relacionada al antigeno carcinoembrionico 1 (ceacam1).
EA201991729A1 (ru) Антитела к tgf-бета и их применение
点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载